Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis.
Géraldine AndrodiasLouise NoroyDimitri PsimarasCristina BirzuJean PelletierYsoline BeigneuxPierre BrangerJonathan CironYannick DananchetRaphael DepazCaroline Froment TiliketeLaurence GignouxClara Grosset-JaninBastien JoubertPhilippe KerschenArnaud KwiatkowskiChristine Lebrun-FrénayElisabeth MaillartAurelien MaureillePhilippe NicolasThomas RouxRomain MarignierBertrand Audoinnull nullPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
Our study suggests that the overall risk of MS activity under ICI is low and could be mainly driven by DMT discontinuation, as in MS in general. Although larger studies are needed for better risk assessment in younger patients with more active disease, ICI should be considered when needed in patients with MS.